Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have voluntarily agreed to take part and have signed a consent form.
• People aged 18 or older at the time of signing the consent form.
• People who have been newly diagnosed (confirmed by laboratory tissue testing) with stage III or IV high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; or certain types of endometrial-like (endometrioid) ovarian cancer grade II or higher; or mixed tumours where the high-grade serous or grade II+ endometrioid part makes up more than half the tumour.
• People who have at least one tumour that can be measured on a CT or MRI scan.
• People whose doctor has determined that complete surgical removal of the tumour is not achievable, or that surgery is not safe for them — based on specific assessment scores from keyhole surgery or CT scan results, or due to factors such as high body weight, multiple ongoing health conditions, poor nutrition, significant fluid build-up in the abdomen, a recent blood clot, reduced ability to carry out daily activities, or other reasons as judged by the treating doctor.
• People with an expected survival of more than 12 weeks.
• People with a general health and activity level rated between 0 and 2 on the ECOG scale (a standard medical scale where 0 means fully active and 2 means able to care for oneself but unable to carry out work activities).
• People who have tested positive for a BRCA1 or BRCA2 gene mutation through professional genetic testing.
• People whose blood test results show that their bone marrow, liver, and kidney function all meet specific minimum levels required by the trial (confirm with trial site for exact values).
• Women who could become pregnant must have had a negative blood pregnancy test within one week before starting treatment, must not be breastfeeding, and must agree to use effective contraception during the study and for 6 months after the last dose of study treatment.
• People who are willing to complete quality-of-life questionnaires during treatment and follow-up, and agree for those results to be used in the research.

Who may not be able to join:

• People who have had another cancer in the past 5 years that has not been treated, with the exception of certain cured skin cancers, cervical carcinoma in situ, or breast cancer with no recurrence for more than 3 years following complete surgical treatment.
• People who have untreated cancer that has spread to the brain or the lining of the brain (people with previously treated and stable brain metastases who meet specific conditions may still be considered — confirm with trial site).
• People who have previously been treated with a PARP inhibitor (a type of targeted cancer medicine) or Bevacizumab (a type of cancer medicine).
• People who are unable to swallow tablets, or who have a digestive system condition that the doctor believes may affect how the body absorbs the study medicine.
• People who have had a bowel blockage or a hole in the bowel or stomach in the past 3 months.
• People with poorly controlled heart conditions, including moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, certain serious heart rhythm problems, or an abnormal heart electrical reading above a specific threshold (confirm with trial site for exact values).
• People who have had significant bleeding symptoms or a clear tendency to bleed in the 3 months before starting treatment, or who have a positive result for hidden blood in their stool at the start of the study (further testing may be needed — confirm with trial site).
• People who have received a platelet or red blood cell transfusion within 14 days before starting treatment.
• People with active ulcers, wounds that have not healed, or fractures.
• People who have had a severe bleeding event (grade 2 or higher on a standard medical scale) within 4 weeks before starting treatment.
• People who have an active infection or an unexplained fever above 38.5°C during the screening period or before starting treatment.
• People with a weakened immune system from birth or from a condition such as HIV, or who have active hepatitis B or C (based on specific blood test results — confirm with trial site).
• People who have received radiotherapy, chemotherapy, hormone therapy, or targeted cancer therapy recently (within 4 weeks of the last dose, or within 5 half-lives for certain oral medicines), or who have not recovered from side effects of previous cancer treatment.
• People who have had a serious blood clot event — such as a stroke, deep vein thrombosis, or pulmonary embolism — within the 6 months before starting treatment.
• People with a known history of inherited or acquired bleeding or clotting disorders, such as haemophilia or platelet problems.
• People who may need to receive other cancer treatments during the study.
• People with high blood pressure that remains uncontrolled despite treatment (systolic blood pressure of 150 mmHg or higher, or diastolic blood pressure of 90 mmHg or higher).
• People who are pregnant, breastfeeding, or planning to become pregnant during the study.
• People who, in the doctor's judgement, have other conditions or circumstances that could put their safety at risk or affect the quality of the study data, such as serious mental health conditions, severe abnormal lab results, or significant personal or social circumstances.

Important: Always verify eligibility with the trial site directly before applying.